Cargando…
Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis
Background: We examined the real-world drug retention rate and safety data of Janus kinase inhibitors (JAKis) in elderly patients with rheumatoid arthritis (RA). Methods: This study enrolled 133 RA patients (≥65 years) with sufficient clinical data who were initiated with JAKis during the study peri...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380728/ https://www.ncbi.nlm.nih.gov/pubmed/37510700 http://dx.doi.org/10.3390/jcm12144585 |
_version_ | 1785080267672649728 |
---|---|
author | Temmoku, Jumpei Miyata, Masayuki Suzuki, Eiji Sumichika, Yuya Saito, Kenji Yoshida, Shuhei Matsumoto, Haruki Fujita, Yuya Matsuoka, Naoki Asano, Tomoyuki Sato, Shuzo Migita, Kiyoshi |
author_facet | Temmoku, Jumpei Miyata, Masayuki Suzuki, Eiji Sumichika, Yuya Saito, Kenji Yoshida, Shuhei Matsumoto, Haruki Fujita, Yuya Matsuoka, Naoki Asano, Tomoyuki Sato, Shuzo Migita, Kiyoshi |
author_sort | Temmoku, Jumpei |
collection | PubMed |
description | Background: We examined the real-world drug retention rate and safety data of Janus kinase inhibitors (JAKis) in elderly patients with rheumatoid arthritis (RA). Methods: This study enrolled 133 RA patients (≥65 years) with sufficient clinical data who were initiated with JAKis during the study period. These patients were divided into two groups: the very elderly group (≥ 75 years) and the elderly group (65 ≤ years < 75). The drug retention rates of JAKis were compared using Kaplan–Meier curves. Results: The discontinuation rates of JAKis were as follows: lack of effectiveness 27 (20.3%), adverse events (AEs) 29 (21.8%), and remission 2 (1.5%). There was no significant difference in the overall drug retention rate between the very elderly group (≥75 years) and the elderly group. Furthermore, the overall drug retention rates of JAKis were not affected by gender, methotrexate use, and anti-citrullinated protein/peptide antibody (ACPA) status. The discontinuation rates of JAKis due to AEs were comparable both in the very elderly group (≥75 years) and the elderly group (65 ≤ years < 75). Whereas chronic lung disease and hypoalbuminemia were independently associated with discontinuation rates due to AEs, the overall drug retention rates were significantly lower in patients treated with the approved dose of JAKis than in those treated with a reduced or tapered dose. Conclusions: Our results suggest that the overall drug retention rate of JAKis in very elderly patients (≥75 years) was comparable with that in elderly patients (65 ≤ years < 75). The discontinuation rates of JAKis due to AEs were also comparable both in very elderly group patients and elderly patients. |
format | Online Article Text |
id | pubmed-10380728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103807282023-07-29 Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis Temmoku, Jumpei Miyata, Masayuki Suzuki, Eiji Sumichika, Yuya Saito, Kenji Yoshida, Shuhei Matsumoto, Haruki Fujita, Yuya Matsuoka, Naoki Asano, Tomoyuki Sato, Shuzo Migita, Kiyoshi J Clin Med Article Background: We examined the real-world drug retention rate and safety data of Janus kinase inhibitors (JAKis) in elderly patients with rheumatoid arthritis (RA). Methods: This study enrolled 133 RA patients (≥65 years) with sufficient clinical data who were initiated with JAKis during the study period. These patients were divided into two groups: the very elderly group (≥ 75 years) and the elderly group (65 ≤ years < 75). The drug retention rates of JAKis were compared using Kaplan–Meier curves. Results: The discontinuation rates of JAKis were as follows: lack of effectiveness 27 (20.3%), adverse events (AEs) 29 (21.8%), and remission 2 (1.5%). There was no significant difference in the overall drug retention rate between the very elderly group (≥75 years) and the elderly group. Furthermore, the overall drug retention rates of JAKis were not affected by gender, methotrexate use, and anti-citrullinated protein/peptide antibody (ACPA) status. The discontinuation rates of JAKis due to AEs were comparable both in the very elderly group (≥75 years) and the elderly group (65 ≤ years < 75). Whereas chronic lung disease and hypoalbuminemia were independently associated with discontinuation rates due to AEs, the overall drug retention rates were significantly lower in patients treated with the approved dose of JAKis than in those treated with a reduced or tapered dose. Conclusions: Our results suggest that the overall drug retention rate of JAKis in very elderly patients (≥75 years) was comparable with that in elderly patients (65 ≤ years < 75). The discontinuation rates of JAKis due to AEs were also comparable both in very elderly group patients and elderly patients. MDPI 2023-07-10 /pmc/articles/PMC10380728/ /pubmed/37510700 http://dx.doi.org/10.3390/jcm12144585 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Temmoku, Jumpei Miyata, Masayuki Suzuki, Eiji Sumichika, Yuya Saito, Kenji Yoshida, Shuhei Matsumoto, Haruki Fujita, Yuya Matsuoka, Naoki Asano, Tomoyuki Sato, Shuzo Migita, Kiyoshi Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis |
title | Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis |
title_full | Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis |
title_fullStr | Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis |
title_full_unstemmed | Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis |
title_short | Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis |
title_sort | drug retention rates and the safety of janus kinase inhibitors in elderly patients with rheumatoid arthritis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380728/ https://www.ncbi.nlm.nih.gov/pubmed/37510700 http://dx.doi.org/10.3390/jcm12144585 |
work_keys_str_mv | AT temmokujumpei drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis AT miyatamasayuki drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis AT suzukieiji drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis AT sumichikayuya drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis AT saitokenji drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis AT yoshidashuhei drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis AT matsumotoharuki drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis AT fujitayuya drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis AT matsuokanaoki drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis AT asanotomoyuki drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis AT satoshuzo drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis AT migitakiyoshi drugretentionratesandthesafetyofjanuskinaseinhibitorsinelderlypatientswithrheumatoidarthritis |